Clinical characteristics of patients undergoing RPFNA
A. Patient characteristics for RPFNA | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
Women enrolled in study | 38 | |||||||||
Bilateral RPFNA | 28 | |||||||||
Unilateral RPFNA | 10 | |||||||||
RPFNA samples collected | 66 | |||||||||
No. RPFNAs with insufficient epithelial cell count | 10 | |||||||||
No. RPFNAs submitted for analysis | 56 | |||||||||
n = 38 (%) | ||||||||||
Average age and range (y) | 46 (29-64) | |||||||||
Race | ||||||||||
Caucasian | 33 (87) | |||||||||
African American | 5 (13) | |||||||||
Menopausal status | ||||||||||
Postmenopausal | 18 (47) | |||||||||
Premenopausal/Perimenopausal | 20 (53) | |||||||||
Hormone replacement use | ||||||||||
Current | 2 (5) | |||||||||
Ever use | 9 (24) | |||||||||
Never use | 27 (71) | |||||||||
Antiestrogen therapy (at the time of RPFNA) | ||||||||||
Tamoxifen | 2 (5) | |||||||||
Raloxifene | 1 (3) | |||||||||
Aromatase inhibitor | 2 (5) | |||||||||
Family history of breast cancer | 17 (45) | |||||||||
Prior abnormal biopsies | ||||||||||
LCIS | 1 (3) | |||||||||
DCIS | 5 (13) | |||||||||
ADH | 10 (26) | |||||||||
History of contralateral breast cancer | 5 (13) | |||||||||
B. Characteristics of patients on prevention therapy at time of RPFNA | ||||||||||
RPFNA sampling | Agent | Duration | Masood | Cell count | M3/M4 methylation | |||||
Unilateral | Tamoxifen | 2 wk | 14 | 500 | +/+ | |||||
Bilateral (L) | Raloxifene | 2 y | 10 | <10 | −/− | |||||
Bilateral (R) | 10 | 10 | −/− | |||||||
Unilateral | Tamoxifen | 2 wk | 15 | 1,000 | +/− | |||||
Unilateral | Aromatase inhibitor | 1 y | NA | NA | −/− | |||||
Unilateral | Aromatase inhibitor | 1 y | NA | NA | −/− |